MoAbs for the Management of Pancreatic Cancer

用于治疗胰腺癌的单克隆抗体

基本信息

  • 批准号:
    6361753
  • 负责人:
  • 金额:
    $ 32.42万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2002
  • 资助国家:
    美国
  • 起止时间:
    2002-04-01 至 2006-03-31
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (provided by applicant): Pancreatic cancer is the ninth most common form of cancer, yet it is the fourth and fifth leading cause of cancer deaths in men and women, respectively. The most common symptoms of the disease are nonspecific in nature. Thus diagnosing pancreatic cancer at an early stage of tumor growth is difficult at best, requiring considerable suspicion and extensive diagnostic workup, up to and including exploratory surgery. Unfortunately then, the vast majority of patients present at a stage when the tumor has extended outside of the capsule to invade surrounding organs, and/or has metastasized extensively. Treatment procedures currently available for pancreatic cancer have not been able to bring about a cure nor substantially improve survival time. The consequence is a 5-year survival rate of less than 3 percent. The long-term objective of this research proposal is the development of monoclonal antibodies for the management of pancreatic cancer (i.e., detection, diagnosis, staging and therapy). We have characterized the PAM4 monoclonal antibody, providing evidence as to its use clinical detection of pancreatic cancer. A general issue in considering the use of radiolabeled antibody as a therapeutic agent for clinical application is that tumor accretion of antibody has been low compared to that achieved in experimental models. In the current research project, we will attempt to overcome this problem by investigating methodologies designed to increase tumor uptake of radiolabeled antibody while maintaining high tumor-nontumor ratios. We will engineer PAM4 antibody constructs having appended peptide signal sequences for internalization and intracellular trafficking. These will be examined to determine which of several organelle trafficking signals provides the highest tumor uptake and retention of antibody targeted radioisotope. In addition, we will examine the role of valence for homofunctional and heterofunctional organelle retention signals appended to the antibody. Finally, a PAM4IL2 fusion protein will be examined for its ability to enhance tumor uptake of a subsequently administered radiolabeled PAM4 antibody.
描述(由申请人提供):胰腺癌是第九常见的 它是一种癌症,但它是癌症死亡的第四和第五大原因 在男性和女性中,分别。这种疾病最常见的症状是 非特异性的因此,在早期阶段诊断胰腺癌, 肿瘤生长是困难的,需要相当大的怀疑, 广泛的诊断检查,包括探查手术。 不幸的是,绝大多数患者都处于一个阶段, 肿瘤已经延伸到包膜外,侵入周围器官,和/或 已经广泛转移目前可用的治疗程序 胰腺癌还不能治愈, 提高生存时间。其结果是5年生存率低于3 百分之这项研究计划的长远目标是发展 用于胰腺癌管理的单克隆抗体(即, 检测、诊断、分期和治疗)。我们已经表征了PAM 4 单克隆抗体,提供证据,其使用的临床检测 胰腺癌在考虑使用放射性标记的 抗体作为临床应用治疗剂是肿瘤 与实验中获得的抗体相比, 模型在当前的研究项目中,我们将尝试克服这一点 通过研究旨在增加肿瘤对 放射性标记的抗体,同时维持高肿瘤-非肿瘤比率。我们将 具有附加的肽信号序列的工程化PAM 4抗体构建体, 内化和细胞内运输。这些将被审查, 确定几种细胞器贩运信号中哪一种提供最高的 肿瘤摄取和抗体靶向放射性同位素的保留。另外我们 将研究化合价对同功能和异功能的作用, 附加到抗体上的细胞器滞留信号。最后,PAM 4 IL 2融合 将检查蛋白质增强肿瘤对A 随后施用放射性标记的PAM 4抗体。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

DAVID V GOLD其他文献

DAVID V GOLD的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('DAVID V GOLD', 18)}}的其他基金

Histology/Immunohistology
组织学/免疫组织学
  • 批准号:
    7728855
  • 财政年份:
    2008
  • 资助金额:
    $ 32.42万
  • 项目类别:
Detection and Diagnosis of Pancreatic Carcinoma
胰腺癌的检测和诊断
  • 批准号:
    7886032
  • 财政年份:
    2005
  • 资助金额:
    $ 32.42万
  • 项目类别:
Detection and Diagnosis of Pancreatic Carcinoma
胰腺癌的检测和诊断
  • 批准号:
    8657815
  • 财政年份:
    2005
  • 资助金额:
    $ 32.42万
  • 项目类别:
Detection and Diagnosis of Pancreatic Cancer
胰腺癌的检测和诊断
  • 批准号:
    7459750
  • 财政年份:
    2005
  • 资助金额:
    $ 32.42万
  • 项目类别:
Detection and Diagnosis of Pancreatic Carcinoma
胰腺癌的检测和诊断
  • 批准号:
    8465742
  • 财政年份:
    2005
  • 资助金额:
    $ 32.42万
  • 项目类别:
Detection and Diagnosis of Pancreatic Carcinoma
胰腺癌的检测和诊断
  • 批准号:
    8257497
  • 财政年份:
    2005
  • 资助金额:
    $ 32.42万
  • 项目类别:
Detection and Diagnosis of Pancreatic Carcinoma
胰腺癌的检测和诊断
  • 批准号:
    8089396
  • 财政年份:
    2005
  • 资助金额:
    $ 32.42万
  • 项目类别:
Detection and Diagnosis of Pancreatic Cancer
胰腺癌的检测和诊断
  • 批准号:
    7271927
  • 财政年份:
    2005
  • 资助金额:
    $ 32.42万
  • 项目类别:
Detection and Diagnosis of Pancreatic Cancer
胰腺癌的检测和诊断
  • 批准号:
    6915870
  • 财政年份:
    2005
  • 资助金额:
    $ 32.42万
  • 项目类别:
Detection and Diagnosis of Pancreatic Cancer
胰腺癌的检测和诊断
  • 批准号:
    7121641
  • 财政年份:
    2005
  • 资助金额:
    $ 32.42万
  • 项目类别:

相似海外基金

Pioneering reproductive biotechnology innovations for equine breeding
开创马匹育种生殖生物技术创新
  • 批准号:
    LP230100156
  • 财政年份:
    2024
  • 资助金额:
    $ 32.42万
  • 项目类别:
    Linkage Projects
Industrial Biotechnology Innovation Cluster
产业生物技术创新集群
  • 批准号:
    EP/Y024168/1
  • 财政年份:
    2024
  • 资助金额:
    $ 32.42万
  • 项目类别:
    Research Grant
Environmental Biotechnology Innovation Centre
环境生物技术创新中心
  • 批准号:
    BB/Y008332/1
  • 财政年份:
    2024
  • 资助金额:
    $ 32.42万
  • 项目类别:
    Research Grant
MFB: Partnerships to Transform Emerging Industries - RNA Tools/Biotechnology: Stabilizing Hairpin Inserts in RNA Virus Induced Gene Silencing Vectors
MFB:合作变革新兴产业 - RNA 工具/生物技术:稳定 RNA 病毒诱导基因沉默载体中的发夹插入
  • 批准号:
    2330663
  • 财政年份:
    2024
  • 资助金额:
    $ 32.42万
  • 项目类别:
    Standard Grant
Conference: Translating Molecular Science Innovations into Biotechnology Solutions
会议:将分子科学创新转化为生物技术解决方案
  • 批准号:
    2419731
  • 财政年份:
    2024
  • 资助金额:
    $ 32.42万
  • 项目类别:
    Standard Grant
Shear Innovation: Valorising wool waste using biotechnology to enhance horticultural peat-free growing media
剪切创新:利用生物技术提高羊毛废料的价值,以增强园艺无泥炭生长介质
  • 批准号:
    10106787
  • 财政年份:
    2024
  • 资助金额:
    $ 32.42万
  • 项目类别:
    Launchpad
NSF Convergence Accelerator Track M: Biofilm-based Corrosion Control using 3D Printed Biotechnology
NSF 融合加速器轨道 M:使用 3D 打印生物技术进行基于生物膜的腐蚀控制
  • 批准号:
    2344389
  • 财政年份:
    2024
  • 资助金额:
    $ 32.42万
  • 项目类别:
    Standard Grant
I-Corps: Translation potential of a miniaturized biotechnology platform for nucleic acid extraction, purification, and library preparation
I-Corps:用于核酸提取、纯化和文库制备的小型生物技术平台的转化潜力
  • 批准号:
    2421022
  • 财政年份:
    2024
  • 资助金额:
    $ 32.42万
  • 项目类别:
    Standard Grant
Engineering Biology Hub for environmental processing and recovery of metals; from contaminated land to industrial biotechnology in a circular economy
用于环境处理和金属回收的工程生物中心;
  • 批准号:
    BB/Y008456/1
  • 财政年份:
    2024
  • 资助金额:
    $ 32.42万
  • 项目类别:
    Research Grant
Development of magnetic force biotechnology to facilitate neural regeneration
开发磁力生物技术促进神经再生
  • 批准号:
    EP/X014126/1
  • 财政年份:
    2023
  • 资助金额:
    $ 32.42万
  • 项目类别:
    Research Grant
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了